Monopar Therapeutics Q3 2025 net loss $3.4M; cash $143.7M; NDA for ALXN1840 planned early 2026

Monopar Therapeutics

Net loss $3.4M ($0.48/sh) vs $1.3M ($0.37/sh) in Q3 2024; no revenue reported.
Cash, equivalents & investments $143.7M as of Sep 30, 2025; funds expected through Dec 2027.
NDA submission to FDA for ALXN1840 in Wilson disease targeted for early 2026.
Raised ~$126.9M gross in public offering; $35M used to repurchase 550,229 shares from Tactic Pharma, net ~$91.9M.
FDA cleared IND for MNPR-101-Lu therapeutic radiopharmaceutical trial in solid tumors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.